Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data DOI Open Access
Pierluigi Puca,

Angelo Del Gaudio,

Jacopo Iaccarino

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 735 - 735

Published: Feb. 21, 2025

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD). These agents offer advantage oral administration have demonstrated efficacy in inducing maintaining remission. However, concerns regarding their safety emerged, particularly concerning cardiovascular infectious complications, which appear more pronounced pre-existing risk factors such as older age, smoking, or comorbidities. While these risks are better understood, potential association between JAK inhibitors malignancies remains a subject ongoing investigation. Current data from randomised controlled trials, pooled integrated analyses, real-world studies provide conflicting evidence cancer risk. Notably, rheumatologic diseases treated contributed additional insights into long-term outcomes. Despite uncertainty surrounding malignancy risks, it is likely that predisposing factors, smoking history, long-standing IBD chronic inflammation, play substantial role development than inhibitor therapy alone. This paper reviews clinical meta-analyses, observational studies, focusing on IBD. We also review rheumatology highlighting need individualised assessment close monitoring to optimise profile medications practice.

Language: Английский

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data DOI Open Access
Pierluigi Puca,

Angelo Del Gaudio,

Jacopo Iaccarino

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 735 - 735

Published: Feb. 21, 2025

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD). These agents offer advantage oral administration have demonstrated efficacy in inducing maintaining remission. However, concerns regarding their safety emerged, particularly concerning cardiovascular infectious complications, which appear more pronounced pre-existing risk factors such as older age, smoking, or comorbidities. While these risks are better understood, potential association between JAK inhibitors malignancies remains a subject ongoing investigation. Current data from randomised controlled trials, pooled integrated analyses, real-world studies provide conflicting evidence cancer risk. Notably, rheumatologic diseases treated contributed additional insights into long-term outcomes. Despite uncertainty surrounding malignancy risks, it is likely that predisposing factors, smoking history, long-standing IBD chronic inflammation, play substantial role development than inhibitor therapy alone. This paper reviews clinical meta-analyses, observational studies, focusing on IBD. We also review rheumatology highlighting need individualised assessment close monitoring to optimise profile medications practice.

Language: Английский

Citations

0